Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors

Shinkichi Takamori, Kazuki Takada, Tetsuzo Tagawa, Gouji Toyokawa, Fumihiko Hirai, Nami Yamashita, Tatsuro Okamoto, Eiji Oki, Tomoharu Yoshizumi, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

Abstract

Background: It has been reported that the tumor microenvironment, including tumor-associated immune cells (ICs) and programmed cell death-ligand 1 (PD-L1) expression, differs between primary and metastatic tumors. This study aimed to elucidate the differences in PD-L1 expression on tumor cells (TCs) and ICs between lung metastases and corresponding primary tumors. Methods: We analyzed paired lesions from 44 patients diagnosed with lung metastases between 2005 and 2017 at Kyushu University. The percentages of PD-L1-positive TCs and ICs in lung metastases and the primary tumor were classified into five categories (0: <1%; 1: 1%–4%; 2: 5%–9%; 3: 10%–49%; and 4: ≥50%). Lesions in which ≥1% of the TCs and ICs were PD-L1-positive were considered positive. Results: The primary cancers included rectal (n = 19), colon (n = 10), liver (n = 10), bile duct (n = 2), stomach (n = 1), gall bladder (n = 1) and breast (n = 1). Discrepancies in PD-L1 expression on TCs and ICs between lung metastases and primary lesions were observed in 5 (11.4%, κ = 0.23) and 9 (20.5%, κ = 0.11) of the 44 cases, respectively. PD-L1 expression on ICs was higher in lung metastases than paired primary tumors (p = 0.026), although the percentage of PD-L1-positive TCs was not significantly different between lung metastases and primary tumors (p = 0.767). Conclusions: There were significant differences in PD-L1 expression on TCs and ICs between lung metastases and primary tumors. Clinicians should be aware of these differences in the tumor microenvironment when treating patients with immunotherapy.

Original languageEnglish
Pages (from-to)637-641
Number of pages5
JournalSurgical Oncology
Volume27
Issue number4
DOIs
Publication statusPublished - Dec 2018

Fingerprint

Cell Death
Neoplasm Metastasis
Ligands
Lung
Neoplasms
Tumor Microenvironment
Rectal Neoplasms
Bile Ducts
Immunotherapy
Stomach
Colon
Urinary Bladder
Breast
Liver

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. / Takamori, Shinkichi; Takada, Kazuki; Tagawa, Tetsuzo; Toyokawa, Gouji; Hirai, Fumihiko; Yamashita, Nami; Okamoto, Tatsuro; Oki, Eiji; Yoshizumi, Tomoharu; Oda, Yoshinao; Maehara, Yoshihiko.

In: Surgical Oncology, Vol. 27, No. 4, 12.2018, p. 637-641.

Research output: Contribution to journalArticle

Takamori, Shinkichi ; Takada, Kazuki ; Tagawa, Tetsuzo ; Toyokawa, Gouji ; Hirai, Fumihiko ; Yamashita, Nami ; Okamoto, Tatsuro ; Oki, Eiji ; Yoshizumi, Tomoharu ; Oda, Yoshinao ; Maehara, Yoshihiko. / Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. In: Surgical Oncology. 2018 ; Vol. 27, No. 4. pp. 637-641.
@article{ac992185606b45ffad5dd19060de1251,
title = "Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors",
abstract = "Background: It has been reported that the tumor microenvironment, including tumor-associated immune cells (ICs) and programmed cell death-ligand 1 (PD-L1) expression, differs between primary and metastatic tumors. This study aimed to elucidate the differences in PD-L1 expression on tumor cells (TCs) and ICs between lung metastases and corresponding primary tumors. Methods: We analyzed paired lesions from 44 patients diagnosed with lung metastases between 2005 and 2017 at Kyushu University. The percentages of PD-L1-positive TCs and ICs in lung metastases and the primary tumor were classified into five categories (0: <1{\%}; 1: 1{\%}–4{\%}; 2: 5{\%}–9{\%}; 3: 10{\%}–49{\%}; and 4: ≥50{\%}). Lesions in which ≥1{\%} of the TCs and ICs were PD-L1-positive were considered positive. Results: The primary cancers included rectal (n = 19), colon (n = 10), liver (n = 10), bile duct (n = 2), stomach (n = 1), gall bladder (n = 1) and breast (n = 1). Discrepancies in PD-L1 expression on TCs and ICs between lung metastases and primary lesions were observed in 5 (11.4{\%}, κ = 0.23) and 9 (20.5{\%}, κ = 0.11) of the 44 cases, respectively. PD-L1 expression on ICs was higher in lung metastases than paired primary tumors (p = 0.026), although the percentage of PD-L1-positive TCs was not significantly different between lung metastases and primary tumors (p = 0.767). Conclusions: There were significant differences in PD-L1 expression on TCs and ICs between lung metastases and primary tumors. Clinicians should be aware of these differences in the tumor microenvironment when treating patients with immunotherapy.",
author = "Shinkichi Takamori and Kazuki Takada and Tetsuzo Tagawa and Gouji Toyokawa and Fumihiko Hirai and Nami Yamashita and Tatsuro Okamoto and Eiji Oki and Tomoharu Yoshizumi and Yoshinao Oda and Yoshihiko Maehara",
year = "2018",
month = "12",
doi = "10.1016/j.suronc.2018.08.001",
language = "English",
volume = "27",
pages = "637--641",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors

AU - Takamori, Shinkichi

AU - Takada, Kazuki

AU - Tagawa, Tetsuzo

AU - Toyokawa, Gouji

AU - Hirai, Fumihiko

AU - Yamashita, Nami

AU - Okamoto, Tatsuro

AU - Oki, Eiji

AU - Yoshizumi, Tomoharu

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2018/12

Y1 - 2018/12

N2 - Background: It has been reported that the tumor microenvironment, including tumor-associated immune cells (ICs) and programmed cell death-ligand 1 (PD-L1) expression, differs between primary and metastatic tumors. This study aimed to elucidate the differences in PD-L1 expression on tumor cells (TCs) and ICs between lung metastases and corresponding primary tumors. Methods: We analyzed paired lesions from 44 patients diagnosed with lung metastases between 2005 and 2017 at Kyushu University. The percentages of PD-L1-positive TCs and ICs in lung metastases and the primary tumor were classified into five categories (0: <1%; 1: 1%–4%; 2: 5%–9%; 3: 10%–49%; and 4: ≥50%). Lesions in which ≥1% of the TCs and ICs were PD-L1-positive were considered positive. Results: The primary cancers included rectal (n = 19), colon (n = 10), liver (n = 10), bile duct (n = 2), stomach (n = 1), gall bladder (n = 1) and breast (n = 1). Discrepancies in PD-L1 expression on TCs and ICs between lung metastases and primary lesions were observed in 5 (11.4%, κ = 0.23) and 9 (20.5%, κ = 0.11) of the 44 cases, respectively. PD-L1 expression on ICs was higher in lung metastases than paired primary tumors (p = 0.026), although the percentage of PD-L1-positive TCs was not significantly different between lung metastases and primary tumors (p = 0.767). Conclusions: There were significant differences in PD-L1 expression on TCs and ICs between lung metastases and primary tumors. Clinicians should be aware of these differences in the tumor microenvironment when treating patients with immunotherapy.

AB - Background: It has been reported that the tumor microenvironment, including tumor-associated immune cells (ICs) and programmed cell death-ligand 1 (PD-L1) expression, differs between primary and metastatic tumors. This study aimed to elucidate the differences in PD-L1 expression on tumor cells (TCs) and ICs between lung metastases and corresponding primary tumors. Methods: We analyzed paired lesions from 44 patients diagnosed with lung metastases between 2005 and 2017 at Kyushu University. The percentages of PD-L1-positive TCs and ICs in lung metastases and the primary tumor were classified into five categories (0: <1%; 1: 1%–4%; 2: 5%–9%; 3: 10%–49%; and 4: ≥50%). Lesions in which ≥1% of the TCs and ICs were PD-L1-positive were considered positive. Results: The primary cancers included rectal (n = 19), colon (n = 10), liver (n = 10), bile duct (n = 2), stomach (n = 1), gall bladder (n = 1) and breast (n = 1). Discrepancies in PD-L1 expression on TCs and ICs between lung metastases and primary lesions were observed in 5 (11.4%, κ = 0.23) and 9 (20.5%, κ = 0.11) of the 44 cases, respectively. PD-L1 expression on ICs was higher in lung metastases than paired primary tumors (p = 0.026), although the percentage of PD-L1-positive TCs was not significantly different between lung metastases and primary tumors (p = 0.767). Conclusions: There were significant differences in PD-L1 expression on TCs and ICs between lung metastases and primary tumors. Clinicians should be aware of these differences in the tumor microenvironment when treating patients with immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85053191009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053191009&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2018.08.001

DO - 10.1016/j.suronc.2018.08.001

M3 - Article

C2 - 30449485

AN - SCOPUS:85053191009

VL - 27

SP - 637

EP - 641

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 4

ER -